LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Cash at Beginning of Period

Last Annual Value

22.98M

3-Year CAGR

180%

5-Year CAGR

85%

10-Year CAGR

36%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Cash at Beginning of Period

LBRX · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
22.98M
2.4%N/AN/A 
32.46M
-35.7%13.2%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
50.53M
-29.0%-28.4%N/A
135.42M
-2.3%-1.2%-0.6%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
95.29M
-14.0%19.0%N/A
97.17M
36.4%28.7%N/A
107.29M
-4.6%-5.3%N/A
76.16M
-10.9%4.5%N/A
4.74M
-63.3%-48.4%N/A
165.00M
5.2%-11.2%7.5%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
59.05M
12.5%8.3%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95